Comparative analysis of the uterine and mammary gland effects of progesterone and medroxyprogesterone acetate

Maturitas

Volumn 65, Issue 4, 2010, Pages 386-391

  Otto, Christiane ^a   Fuchs, Iris ^a   Vonk, Richardus ^a   Fritzemeier, Karl Heinrich ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Hormone replacement therapy; Mammary gland; Progesterone; Proliferation; Synthetic progestins; Uterus

Indexed keywords

ESTRADIOL; ESTRONE; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENDOMETRIUM; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; MAMMARY GLAND; MITOGENESIS; MOUSE; NONHUMAN; OVARIECTOMY; UTERUS;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL PROLIFERATION; DRUG INTERACTIONS; ESTRADIOL; ESTROGENS; FEMALE; MAMMARY GLANDS, ANIMAL; MEDROXYPROGESTERONE ACETATE; MICE; MICE, INBRED C57BL; UTERUS;

MUS;

EID: 77649185147     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.11.028     Document Type: Article

References (20)

1. Oelkers W.K. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 61 4 (1996) 166-171
2. Sitruk-Ware R. New progestogens. A review of their effects in perimenopausal and postmenopausal women. Drugs Aging 21 (2004) 865-883
3. Koubovec D., Ronacher K., Stubsrud E., Louw A., and Hapgood J.P. Synthetic progestins used in HRT have different glucocorticoid agonist properties. Mol Cell Endocrinol 242 (2005) 23-32
4. Hulka B.S., Chambless L.E., Kaufman D.G., Fowler Jr. W.C., and Greenberg B.G. Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 247 (1982) 475-477
5. Said T.K., Conneely O., Medina D., O'Malley B.W., and Lydon J.P. Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. Endocrinology 138 (1997) 3933-3939
6. Hofseth L.J., Raafat A.M., Osuch J.R., Pathak D.R., Slomski C.A., and Haslam S.Z. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84 12 (1999) 4559-4565
7. Clarke R.B., Howell A., Potten C.S., and Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57 (1997) 4987-4991
8. Mulac-Jericevic B., Lydon J.P., DeMayo F.J., and Conneely O.M. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA 100 (2003) 9744-9749
9. Anderson E., and Clarke R.B. Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia 9 (2004) 3-13
10. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
11. Writing Group for the Women's Health Initiative Investigators. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291 (2004) 1701-1712
12. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107 (2008) 103-111
13. Otto C., Fuchs I., Altmann H., et al. Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate. Endocrinology 149 (2008) 3952-3959
14. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat 7 (1979) 1-26
15. Efron B., and Tibshirani R. Bootstrap methods for standard errors, confidence interval, and other measures of statistical accuracy. Stat Sci 1 (1986) 54-75
16. Elger W., Beier S., Pollow K., Garfield R., Qing Shi A., and Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids 68 (2003) 891-905
17. Reichardt H.M., Horsch K., Groene H.-J., et al. Mammary gland development and lactation are controlled by different glucocorticoid receptor activities. Eur J Endocrinol 145 (2001) 519-527
18. Wintermantel T.M., Bock D., Fleig V., Greiner E.F., and Schütz G. The epithelial glucocorticoid receptor is required for the normal timing of cell proliferation during mammary lobuloalveolar development but is dispensable for milk production. Mol Endocrinol 19 (2005) 340-349
19. Kingsley-Kallesen M., Mukhopadhyay S.S., Wyszomierski S.L., Schanler S., Schütz G., and Rosen J.M. The mineralocorticoid receptor may compensate for the loss of the glucocorticoid receptor at specific stages of mammary gland development. Mol Endocrinol 16 (2002) 2008-2018
20. Panoulis C., Lambrinoudaki I., Vourtsi A., et al. Progestin may modify the effect of low-dose hormone therapy on mammographic breast density. Climacteric 12 (2009) 240-247